Montreal, Quebec—The healthcare costs associated with rheumatoid arthritis (RA) have been a growing cause of concern because of the chronic aspect of the disease, treatment costs, and variability in patterns of care, according to researchers.
Applying medical expenditure data to disease severity scores
By Barbara Schwedel
Washington, DC—Mapping disease severity into a panel of economic data can help to predict the marginal economic effects of increasing severity of rheumatoid arthritis (RA), according to a first economic analysis of its type presented at a poster session during the 2012 International Society for Pharmacoeconomics and Outcomes Research annual meeting.
Washington, DC—National and international rheumatology groups have defined the goals of the treat-to-target strategy in rheumatoid arthritis (RA) as achieving disease remission or as low disease activity level.
Results 1 - 7 of 7